Fusion biopsy combines state-of-the-art imaging with the safe and precise procedure of perineal prostate biopsy. Tissue extraction is made specifically from the areas of the prostate suspected to be affected by a tumour. Thus, our patients profit from the latest available technology.
If prostate cancer is suspected, a biopsy is necessary, i.e., a sample taken from the prostate. This suspicion is raised by an elevated PSA blood level, or an abnormal palpation. Regular biopsies are also carried out within the scope of the so-called active monitoring in the case of less aggressive prostate cancer.
In conventional biopsies, about 12 to 16 samples are taken under local anaesthetic through the rectum and under ultrasonic monitoring. Since suspicious areas in the prostate cannot be reliably visualized by ultrasound technology, the samples are removed according to a diagram but not a targeted one. In contrast, fusion biopsies involve at first a high-resolution magnetic resonance imaging (MRI) of the prostate. This helps identifying suspected tumour areas in the prostate with a high degree of certainty. Within the scope of fusion biopsy, the samples are then taken directly from the suspicious areas.
uro, fusion biopsies of the prostate are carried out under a short anaesthesia from
the perineum. All areas of the prostate can be reached with a high degree of
accuracy via this access. The risk of infections is minimal compared to a
biopsy through the rectum. The MRI images are then superimposed on the
ultrasound images of the prostate in real time using the latest computer
technology. Subsequently, targeted samples are taken. The tissue is then sent
to the laboratory for analysis. Usually, the result is available after 2-3